- Examination of faecal calprotectin helps to avoid medical errors - interview2012 | First Faculty of Medicine
- The Accuracy of a Home-performed Faecal Calprotectin Test in Paediatric Patients With Inflammatory Bowel Disease2019 | Second Faculty of Medicine
- Importance of faecal calprotectin in screening and clinical assessment of adult and pediatric patients with inflammatory bowel diseases2016 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Physical Education and Sport
- Diagnostic accuracy of two faecal calprotectin immunoassaysPublication without faculty affiliation
- Calprotectin Levels in Patients with Inflammatory Bowel Disease - Comparison of Two Commercial Tests2008 | First Faculty of Medicine
- Calprotectin Levels in Patients with Inflammatory Bowel Disease - Comparison of Two Commercial Tests2008 | Publication without faculty affiliation
- Report about nationwide interlaboratory comparisons of the examination of faecal calprotectin2014 | First Faculty of Medicine
- Paediatric Rome III Criteria-Related Abdominal Pain Is Associated With Helicobacter pylori and Not With Calprotectin2016 | Faculty of Medicine in Pilsen
- New approaches in the follow-up of patients suffering from inflammatory bowel diseases2015 | First Faculty of Medicine
- The Role and Importance of Screening in Gastrointestinal Disease2012 | First Faculty of Medicine
- From bruising a toe to diagnosing cystic fibrosis2016 | First Faculty of Medicine, Second Faculty of Medicine
- Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial2017 | First Faculty of Medicine, Central Library of Charles University
- Biosimilar infliximab in anti-TNF naive inflammatory bowel disease patients - one-year clinical follow-upPublication without faculty affiliation
- Laboratory screening markers in gastroenterology - state of the art2013 | First Faculty of Medicine
- Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors +1First Faculty of Medicine, Second Faculty of Medicine
- Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre2020 | First Faculty of Medicine
- Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation2016 | First Faculty of Medicine, Second Faculty of Medicine
- The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update2021 | Second Faculty of Medicine
- First experience of vedolizumab in paediatric IBD patients +12019 | Second Faculty of Medicine
- Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II2021 | Faculty of Medicine in Hradec Králové
- Overview of biomarkers and their relationship to axial spondyloarthritis associated with idiopathic inflammatory bowel diseases2021 | First Faculty of Medicine
- A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts2022 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Switch from original to biosimilar adalimumab SB-5 in patients with Crohn's disease - long-term results2021 | First Faculty of Medicine